{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Grade I"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}],"title":"Grade IIA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"7"}]}],"title":"Grade IIB"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}]}],"title":"Grade III"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"The effect of adding bevacizumab to preoperative chemotherapy comprised of cisplatin, doxorubicin, and HDMTX on the histologic response in patients with localized resectable osteosarcoma compared to historical controls treated with preoperative cisplatin, doxorubicin, and HDMTX without bevacizumab on the Intergroup Study 0133.\n\nHistologic response at week 10 of therapy was evaluated by Huvos grading systems as grade I: tumor not responding to therapy, no effect identified; grade IIA: more than 50% viable tumor left; grade IIB: 5-50% viable tumor remaining; grade III: only scattered foci of viable tumor seen (less than 5% of tumor); grade IV: no viable tumor seen in extensive sampling (at least a full cross-section of the tumor).\n\nThe study did not enroll an adequate number of participants, therefore, the comparison to Intergroup Study 0133 participants was not done.","groups":[{"description":"Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.","id":"OG000","title":"A: Localized Resectable Disease"},{"description":"Stratum C participants had metastatic tumors.","id":"OG001","title":"C: Metastatic Tumors"}],"paramType":"NUMBER","populationDescription":"All Stratum A participants were evaluated. The tumor sample for analysis was not obtained for one of the 12 Stratum C participants.","reportingStatus":"POSTED","timeFrame":"After 6 cycles of chemotherapy, up to 1 year after the start of therapy","title":"Histologic Response by Stratum","type":"SECONDARY","unitOfMeasure":"participants"}